losartan has been researched along with Hemorrhagic Shock in 1 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Truse, R | 1 |
| Voß, F | 1 |
| Herminghaus, A | 1 |
| Schulz, J | 1 |
| Weber, APM | 1 |
| Mettler-Altmann, T | 1 |
| Bauer, I | 1 |
| Picker, O | 1 |
| Vollmer, C | 1 |
1 other study available for losartan and Hemorrhagic Shock
| Article | Year |
|---|---|
Local gastric RAAS inhibition improves gastric microvascular perfusion in dogs.
Topics: Angiotensins; Animals; Dogs; Female; Gastric Mucosa; Hemodynamics; Hemorrhage; Intestines; Laser-Dop | 2019 |